{
    "clinical_study": {
        "@rank": "146332", 
        "arm_group": [
            {
                "arm_group_label": "intravenous & intramuscular oxytocin", 
                "arm_group_type": "Experimental", 
                "description": "intravenous or intramuscular 10 iu oxytocin"
            }, 
            {
                "arm_group_label": "after delivery & when anterior shoulder seen", 
                "arm_group_type": "Active Comparator", 
                "description": "oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the efficacy of the route and timing of oxytocin administration for Active\n      management of third stage of labour (AMTSL)."
        }, 
        "brief_title": "When and How to Administer Oxytocin for Active Management of Third Stage of Labour", 
        "completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "condition": "Postpartum Bleeding", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Postpartum Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "Our objective is to determine the most efficient route and timing of oxytocin administration\n      by measuring the duration of third stage of labour, quantitative blood during the first hour\n      after delivery and comparing haemoglobin and haematocrit changes and the need for additional\n      interventions in patients who had either a spontaneous labour or received labour\n      augmentation with oxytocin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  having a singleton pregnancy above 37th gestational week\n\n          -  normal live vaginal delivery with cephalic presentation\n\n          -  being in active labor\n\n        Exclusion Criteria:\n\n          -  Fetal demise\n\n          -  multiple pregnancy\n\n          -  known coagulation disorder\n\n          -  presentation anomalies\n\n          -  placental pathology\n\n          -  liver disease\n\n          -  thrombocytopenia\n\n          -  hypertension or being currently on anticoagulants\n\n          -  having a cesarean section, operative delivery or deep vaginal tear\n\n          -  chorioamnionitis\n\n          -  developing HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count)\n             or DIC (disseminated intravascular coagulation) before delivery"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954186", 
            "org_study_id": "EtlikWHTH"
        }, 
        "intervention": [
            {
                "arm_group_label": "after delivery & when anterior shoulder seen", 
                "description": "intravenous or intramuscular 10 iu oxytocin", 
                "intervention_name": "intravenous & intramuscular oxytocin", 
                "intervention_type": "Drug", 
                "other_name": "Postuitrin"
            }, 
            {
                "arm_group_label": "intravenous & intramuscular oxytocin", 
                "description": "oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered", 
                "intervention_name": "after delivery of the fetus & when anterior shoulder seen", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oxytocin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Oxytocin", 
            "Active Management of Third Stage of Labour"
        ], 
        "lastchanged_date": "September 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ankara", 
                    "country": "Turkey"
                }, 
                "name": "Etlik Z\u00fcbeyde Han\u0131m Women's Health Teaching and Research Hospital"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "official_title": "When and How to Administer Oxytocin for Active Management of Third Stage of Labour", 
        "overall_official": [
            {
                "affiliation": "Etlik Z\u00fcbeyde Han\u0131m Women's Health Teaching and Research Hospital, Obstetrics and Gynecology, Ankara, Turkey ,", 
                "last_name": "Berna DILBAZ, Assoc. Prof.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Sivas State Hospital", 
                "last_name": "Emire OGUZ ORHAN, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Etlik Z\u00fcbeyde Han\u0131m Women's Health Teaching and Research Hospital, Obstetrics and Gynecology, Ankara, Turkey", 
                "last_name": "Sezin ERTURK AKSAKAL, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hacettepe University Kastamonu Medical Faculty, Obstetrics and Gynecology, Ankara, Turkey,", 
                "last_name": "Sibel ALTINBAS, Assist. Prof.", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Zekai Tahir Burak Maternity and Teaching Hospital, Obstetrics and Gynecology, Ankara, Turkey", 
                "last_name": "Salim ERKAYA, Assoc. Prof.", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "postpartum bleeding in the third stage of labour", 
            "safety_issue": "Yes", 
            "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954186"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Etlik Zubeyde Hanim Womens' Health and Teaching Hospital", 
            "investigator_full_name": "SEZ\u0130N ERTURK AKSAKAL", 
            "investigator_title": "gynecologist and obstetrician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Etlik Zubeyde Hanim Womens' Health and Teaching Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Etlik Zubeyde Hanim Womens' Health and Teaching Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}